| | POLISH FINANCIAL SUPERVISION AUTHORITY | |
| | | | | UNI - EN REPORT No | 99 | / | 2016 | | | |
| | Date of issue: | 2016-11-04 | | | | | | | | |
| | Short name of the issuer | | | | | | | |
| | SOPHARMA AD | |
| | Subject | | | | | | | | | | |
| | Notification - Veta Pharma AD | |
| | Official market - legal basis | | | | | | |
| | art. 17. 1 MAR. | |
| | Unofficial market - legal basis | | | | | |
| | Contents of the report: | | | | | | | | |
| | The Board of Directors of Sopharma AD decided to purchase up to 100% of the capital of “Veta Pharma" AD for a price not exceeding 2.12 BGN per share. The Board authorised the Executive Director to undertake all necessary legal actions thereby.
“Veta Pharma" AD is a modern and dynamic Bulgarian pharmaceutical porducer of 47 different products divided in three categories: medicinal products, food additives and cosmetic products. The volume of sales for 2015 exceeds 3 million packages on the Bulgarian pharmaceutical market. 50 people work at the company.
“Veta Pharma" AD plans, produces and distributes its products in accordance with the Good Manufacturing Practice _GMP_ and the standards applied by the Bulgarian and European legal framewok.
| |
| | Annexes | | | | | | | | | | |
| | File | Description | |
| | | Notification - Veta Pharma AD | |
